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We evaluated the interaction between hepatitis C virus (HCV) and cigarette smoking on death from hepatocellular cancer in The
Japan Collaborative Cohort Study. The odds ratio of death from HCC for smoking was 9.60 (1.50–61.35) and 1.71(0.58–5.08)
among anti-HCV positive and negative individuals, respectively.
British Journal of Cancer (2006) 94, 737–739. doi:10.1038/sj.bjc.6602981 www.bjcancer.com
Published online 7 February 2006
& 2006 Cancer Research UK
Keywords: HCC; HCV; JACC study; epidemiology; Japanese
                                    
Many studies have reported that chronic hepatitis C virus (HCV)
infection is a risk factor for hepatocellular carcinoma (HCC) (Mori
et al, 2000; El-Serag, 2002; Sun et al, 2003; Ayoola and Gadour,
2004), HCV appearing to be more hepatocarcinogenic than
hepatitis B virus (HBV) (Pang et al, 2005). While alcohol is a
well established risk factor for HCC, there is evidence that cigarette
smoking is also a risk factor (Mukaiya et al, 1998; Mizoue et al,
2000; Chen et al, 2003), though some studies reported no or an
insignificant association (La Vecchia et al, 1988; Evans et al, 2002).
Recently, an association between diabetes mellitus and HCC (or
HCV) has been reported (Caronia et al, 1999; Toyoda et al, 2001).
We evaluated the interaction between HCV infection and cigarette
smoking by means of a nested case–control study from a large
cohort.
MATERIALS AND METHODS
The Japan Collaborative Cohort Study (JACC Study) for Evaluation
of Cancer Risk sponsored by the Ministry of Education, Science,
Sports and Culture of Japan (Monbusho) is a large prospective
cohort study, which was mounted from 1988 to 1990 in 45 areas in
Japan. The number of subjects is 110792 (46465 males and 64327
females) who were 40–79 years of age at the time of the baseline
survey. Individual informed consent to participate in the study was
obtained in 36 out of 45 areas (Tamakoshi et al, 2005). The
subjects were asked to complete a self-administered questionnaire
about past medical history, various life style factors and marital
status as baseline information. The detailed design of the JACC
study has been described previously (Ohno and Tamakoshi,
2001; Watanabe et al, 2005). During the approximately 10 years
of follow-up through December 31, 1999, there were 550 deaths
from liver cancer that were coded as C22 in the International
Classification of Diseases and Related Health Problems, 10th
Revision. Those survey participants who underwent health-
screening checks sponsored by municipalities were asked to
donate blood samples during the same period as the questionnaire
survey. Eventually, 39242 subjects provided blood samples
(Tamakoshi et al, 2005). Baseline serum samples had been
collected 120 of the 550 subjects who died of liver cancer. As the
control group, sera of 11543 subjects from the same geographical
areas as the 120 deaths also were screened for anti-HCV. Deaths
(nine) coded as C22.9 (liver cancer not otherwise specified) were
excluded from this analysis, while deaths (five) coded as C22.1
(intrahepatic cholangiocarcinoma and cholangiohepatoma; in-
cluded among non-HCC deaths), leaving 106 deaths from HCC
that were regarded as the end point of this analysis. The total
subjects were 11654 but as the sera of 34 cases and controls could
not be screened because of insufficient serum volume, the sera of
11620 subjects were screened for antibody to HCV (anti-HCV) and
then divided into anti-HCV positiveand anti-HCV negative groups.
In each group, the cases were deaths due to HCC. The controls
(living) were individually matched with cases for age (73 years),
gender and area, the cases or the controls that could not be
matched being eliminated from this analysis; in the end, there were
3431 subjects.
We used SAS version 8.2 software (SAS institute, Cary, NC,
USA) for the statistical analysis. Baseline information on smoking
habits was divided into three groups. Matched multivariate-
adjusted odds ratios (OR) and 95% confidence interval (CI) for
risk factors for death due to HCC were estimated after adjusting
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yfor potential confounding factors (alcohol-drinking habit, past
history of liver disease and past history of diabetes mellitus) using
a conditional logistic model. With respect to interaction between
HCV and smoking habits on HCC risk, we evaluated this by
examining whether the odds ratio of death from HCC for each
factor differed between anti-HCV positive group and anti-HCV
negative group.
RESULTS
Table 1 provides details of the HCC cases and matched controls by
cigarette smoking habits. Subjects who lacked data on the adjusted
factor were eliminated from the multivariate analysis (Table 2).
In the anti-HCV positive group, the OR of death due to HCC
was 7.84 (95% CI: 1.09–56.05) for ex-smokers and 9.60 (95% CI:
1.50–61.36) for current smokers. The OR for ‘o35’ and ‘35 or
more’ of smoking period were 11.02 (95% CI: 1.67–72.64) and 6.99
(95% CI: 1.03–47.51), respectively. The OR for smoking on average
‘10 to 19 and ‘20 or more’ cigarettes per day were 12.47 (95% CI:
1.82–85.56) and 9.10 (95% CI: 1.10–75.05), respectively. We found
no significant association between HCC and smoking period or
average number in anti-HCV negative group.
DISCUSSION
There are a few reports evaluating the joint effect of HCV infection
and smoking habits on HCC. Sun et al (2003) suggest that the
adjusted relative risk of HCC development was 3.9 for smokers
who were positive for anti-HCV in comparison with that for
nonsmokers who were negative for anti-HCV. Yu et al (1991)
reported that there were significantly synergistic effects of anti-
HCV with cigarette smoking. We performed multivariate analysis
of an interaction between smoking habits and HCV on death from
HCC controlling the potential confounding factors in the JACC
study. Our results showed that cigarette smoking was associated
with significantly elevated risk of developing HCC only among
anti-HCV positive individuals. Much evidence indicates that the
initiation or progression of HCC is a multistage process in which
many factors are involved (Durr and Caselmann, 2000). The effect
of cigarette smoking on persons with anti-HCV may involve
promoting the progression from hepatitis to cirrhosis or from
cirrhosis to HCC. In conclusion, we had observed an interaction
between HCV infection and cigarette smoking on risk of death
from HCC.
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Table 1 Distribution of the HCC cases and matched controls by
smoking habits, smoking period and smoking average number
Anti-HCV positive group Anti-HCV negative group
Case (%) Control (%) Control (%) Case (%)
Smoking habits
Never smoker 13 (22.4) 241 (56.0) 16 (44.4) 1712 (58.9)
Ex smoker 8 (13.8) 54 (12.6) 5 (13.9) 378 (13.0)
Current smoker 30 (51.7) 116 (27.0) 15 (41.7) 688 (23.7)
Unknown 7 (12.1) 19 (4.4) 0 (0.0) 129 (4.4)
Total 58 (100.0) 430 (100.0) 36 (100.0) 2907 (100.0)
Smoking period (year)
Never smoker 13 (27.1) 241 (60.9) 16 (44.4) 1712 (63.0)
o35 13 (27.1) 54 (13.6) 6 (16.7) 467 (17.2)
35 or more 22 (45.8) 101 (25.5) 14 (38.9) 538 (19.8)
Total 48 (100.0) 396 (100.0) 36 (100.0) 2717 (100.0)
Smoking average number (cig/day)
Never smoker 13 (26.5) 241 (59.2) 16 (45.7) 1712 (62.2)
o10 0 (0.0) 13 (3.2) 1 (2.9) 85 (3.1)
10 to 19 13 (26.5) 49 (12.0) 6 (17.1) 336 (12.2)
20 or more 23 (47.0) 104 (25.6) 12 (34.3) 618 (22.5)
Total 49 (100.0) 407 (100.0) 35 (100.0) 2751 (100.0)
Table 2 Odds ratio (OR) of death from HCC by characteristics of smoking habits, smoking period and smoking average number
Anti-HCV positive group Anti-HCV negative group
Case Control OR
a 95% CI Case Control OR
a 95% CI
Smoking habits
Never smoker 13 220 1.00 13 1604 1.00
Exsmoker 7 44 7.84 1.09–56.05 2 339 0.28 0.05–1.71
Current smoker 23 104 9.60 1.50–61.36 14 623 1.71 0.58–5.08
Smoking period (year)
Never smoker 13 220 1.00 13 1604 1.00
o35 11 46 11.02 1.67–72.64 3 425 0.49 0.10–2.33
35 or more 16 89 6.99 1.03–47.51 13 488 2.41 0.63–9.21
Smoking average number (cig/day)
Never smoker 13 220 1.00 13 1604 1.00
o10 0 11 — — 1 76 1.00 0.11–8.84
10 to 19 12 45 12.47 1.82–85.56 4 303 0.84 0.21–3.38
20 or more 16 89 9.10 1.10–75.05 10 556 1.27 0.38–4.20
aAdjusted for area, age, gender, past history of diabetes mellitus, past history of liver diseases and alcohol drinking habits.
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